Ramipril in High-Risk Patients With COVID-19

Journal of the American College of Cardiology

Volumn 76, Issue 3, 2020, Pages 268-276

  Amat Santos, Ignacio J ^a   Santos Martinez, Sandra ^a   López Otero, Diego ^b   Nombela Franco, Luis ^c   Gutiérrez Ibanes, Enrique ^d   Del Valle, Raquel ^e   Muñoz García, Erika ^f   Jiménez Diaz, Víctor A ^g   Regueiro, Ander ^h   González Ferreiro, Rocío ⁱ   Benito, Tomás ^j   Sanmartin Pena, Xoan Carlos ^b   Catalá, Pablo ^a   Rodríguez Gabella, Tania ^a   Delgado Arana, Jose Raúl ^a   Carrasco Moraleja, Manuel ^a   Ibañez, Borja ^k   San Román, J Alberto ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b CIBERCV   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g UNIVERSITY OF VIGO   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL UNIVERSITARIO DE LEÓN   (Spain)

^k CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

more..

Author keywords

COVID 19; renin angiotensin; SARS CoV 2; transcatheter aortic valve replacement

Indexed keywords

RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; AGING; AORTIC STENOSIS; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; COMORBIDITY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; FEMALE; HEMATOCRIT; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; OXYGEN SUPPLY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SOCIETY OF THORACIC SURGEONS SCORE; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT DURATION; VERY ELDERLY; BETACORONAVIRUS; CLINICAL TRIAL; CORONAVIRUS INFECTION; EPIDEMIOLOGY; MORTALITY; PANDEMIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPAIN; VIRUS PNEUMONIA;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; MALE; PANDEMICS; PNEUMONIA, VIRAL; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SPAIN;

EID: 85087386585     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2020.05.040     Document Type: Article

References (34)

1. Corman, V.M., Lienau, J., Witzenrath, M., Coronaviruses as the cause of respiratory infections. Internist (Berl) 60 (2019), 1136–1145.
2. Zhong, N.S., Zheng, B.J., Li, Y.M., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 362 (2003), 1353–1358.
3. Drosten, C., Günther, S., Preiser, W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1967–1976.
4. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
5. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
6. Zhu, N., Zhang, D., Wang, W., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382 (2020), 727–733.
7. Zhou, P., Yang, X.L., Wang, X.G., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (2020), 270–273.
8. Lu, R., Zhao, X., Li, J., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395 (2020), 565–574.
9. Chan, J.F., Yuan, S., Kok, K.H., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395 (2020), 514–523.
10. Li, W., Moore, M.J., Vasilieva, N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:6965 (2003), 450–454.
11. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181 (2020), 271–280.e8.
12. Hamming, I., Timens, W., Bulthuis, M.L., Lely, A.T., Navis, G., van Goor, H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol 203 (2004), 631–637.
13. Ferrario, C.M., Jessup, J., Chappell, M.C., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005), 2605–2610.
14. Danser, A.H.J., Epstein, M., Batlle, D., Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 75 (2020), 1382–1385.
15. Wang, K., Gheblawi, M., Oudit, G.Y., Angiotensin converting enzyme 2: a double-edged sword. Circulation, 2020 Mar 26 [E-pub ahead of print].
16. Sommerstein, R., Kochen, M.M., Messerli, F.H., Grani, C., Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?. J Am Heart Assoc, 9, 2020, e016509.
17. Imai, Y., Kuba, K., Rao, S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (2005), 112–116.
18. Meng, J., Xiao, G., Zhang, J., et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9 (2020), 757–760.
19. Rodriguez-Gabella, T., Catalá, P., Muñoz-García, A.J., et al. Renin-angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol 74 (2019), 631–641.
20. Amat-Santos, I.J., Catalá, P., Diez Del Hoyo, F., et al. Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open, 8, 2018, e020255.
21. World Health Organization. Coronavirus Disease 2019: Situation Report–76. April 5, 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4. (Accessed 6 April 2020)
22. Zhong, J., Basu, R., Guo, D., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
23. Fang, L., Karakiulakis, G., Roth, M., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med, 8, 2020, e21.
24. Esler, M., Esler, D., Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?. J Hypertens 38 (2020), 781–782.
25. Diaz, J.H., Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med, 27, 2020 taaa041.
26. Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer, M.A., Solomon, S.D., Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382 (2020), 1653–1659.
27. Bozkurt, B., Kovacs, R., Harrington, B., HFSA/ACC/AHA Statement Addressed Concerns Re: Using RAAS Antagonists in COVID-19. ACC news story, March 17, 2020 Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19 Accessed May 15, 2020.
28. Wu, C., Chen, X., Cai, Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 2020 Mar 13 [E-pub ahead of print].
29. Garg, S., Kim, L., Whitaker, M., et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 69 (2020), 458–464.
30. Richardson, S., Hirsch, J.S., Narasimhan, M., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 323 (2020), 2052–2059.
31. Dietz, W., Santos-Burgoa, C., Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring), 28, 2020, 1005.
32. Puig-Domingo, M., Marazuela, M., Giustina, A., COVID-19 and endocrine diseases: a statement from the European Society of Endocrinology. Endocrine 68 (2020), 2–5.
33. Kuster, G.M., Pfister, O., Burkard, T., et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?. Eur Heart J 41 (2020), 1801–1803.
34. Patel, A.B., Verma, A., COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?. JAMA, 2020 Mar 24 [E-pub ahead of print].